 To determine the effect of Rimonabant 20mg on the co-primary endpoint including Fasting Plasma Glucose FPG, HDL-Cholesterol HDL-C and triglyceride TG levels over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with impaired fasting blood glucose and with or without associated comorbidities. 